HCW Biologics (HCWB) shares are cooling off Tuesday after a blistering rally that saw the stock soar 262% last week. The biotech company's stock was down about 17% at $1.12 in afternoon trading, as retail traders locked in gains following the explosive move.
But don't let the red day fool you — the stock is still way up from where it was a week ago. Tuesday's decline is mostly about profit-taking, not a change in the company's story. The broader market isn't helping either, with Nasdaq futures down 0.75% and S&P 500 futures off 0.41%, adding some extra pressure.
What Sparked the Rally?
The fireworks started after HCW Biologics reported first-quarter earnings that blew past expectations. The company posted earnings per share of 37 cents and quarterly sales of $6.54 million, up from $5.06 million a year ago. That's a solid beat, and investors took notice.
But the earnings weren't the only catalyst. The company also announced an exclusive worldwide licensing agreement with Trimmune, covering the in vivo rights for HCW11-006, a candidate in its autoimmune pipeline. And there's more on the horizon: preliminary clinical data for HCW9302 in alopecia areata is expected in the first half of 2026.
CEO Hing Wong explained why HCW9302 is the lead candidate: "HCW9302 was selected as the lead product candidate for the company's autoimmune program because it has demonstrated relatively high IL-2Rα affinity and sustains serum exposure, which implies it has a strong profile for the treatment of autoimmune disorders."
On the balance sheet side, the company reported cash and equivalents of $1.23 million, down from $1.95 million a year ago. That's something to keep an eye on, but for now, the pipeline news has investors excited.
Technical Levels to Watch
After such a big move, the stock is in interesting territory from a technical perspective. It's trading 171% above its 20-day simple moving average (SMA) of 47 cents and 169% above its 50-day SMA of 48 cents. But it's still 40.7% below its 200-day SMA of $2.16, which means the longer-term trend is still cautious despite the recent bounce.
The big red flag is momentum: the Relative Strength Index (RSI) is at 84.20, which is deep into overbought territory. That doesn't mean the stock can't go higher, but it does suggest the move is stretched and vulnerable to pullbacks or choppy consolidation.
The moving average structure is still mixed-to-bearish longer term, with the 20-day below the 50-day and the 50-day below the 200-day. So while the short-term action has been impressive, the stock has some work to do to convince the longer-term trend followers.
Key levels to watch: resistance at $2.16 (the 200-day SMA) and support at $1.01. If the stock can hold above that support, the rally might have more room to run. If it breaks below, the profit-taking could get uglier.
For now, it's a classic case of a small biotech stock catching a wave of good news — and then taking a breather as traders decide whether to ride it further or cash out.
